Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives $16.70 Consensus PT from Analysts

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) has earned a consensus rating of "Moderate Buy" from the eleven ratings firms that are currently covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, seven have assigned a buy rating and two have given a strong buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $16.60.

A number of equities analysts recently issued reports on YMAB shares. Morgan Stanley reduced their target price on Y-mAbs Therapeutics from $11.00 to $7.00 and set an "underweight" rating for the company in a research note on Wednesday, March 5th. HC Wainwright reduced their target price on Y-mAbs Therapeutics from $12.00 to $11.00 and set a "buy" rating for the company in a research note on Monday. Oppenheimer reduced their target price on Y-mAbs Therapeutics from $21.00 to $20.00 and set an "outperform" rating for the company in a research note on Wednesday, May 14th. Truist Financial reduced their target price on Y-mAbs Therapeutics from $18.00 to $14.00 and set a "buy" rating for the company in a research note on Wednesday, May 14th. Finally, Bank of America lowered Y-mAbs Therapeutics from a "neutral" rating to an "underperform" rating and set a $3.00 price objective for the company. in a research note on Tuesday, April 22nd.

Y-mAbs Therapeutics Stock Performance

YMAB stock traded up $0.06 during trading on Thursday, reaching $4.23. The company had a trading volume of 112,150 shares, compared to its average volume of 313,826. The firm has a 50-day simple moving average of $4.44 and a 200-day simple moving average of $6.91. The company has a market cap of $191.55 million, a price-to-earnings ratio of -7.83 and a beta of 0.53. Y-mAbs Therapeutics has a twelve month low of $3.55 and a twelve month high of $16.11.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last released its earnings results on Tuesday, May 13th. The company reported ($0.12) EPS for the quarter, topping analysts' consensus estimates of ($0.22) by $0.10. The company had revenue of $20.90 million during the quarter, compared to analysts' expectations of $19.97 million. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. Sell-side analysts expect that Y-mAbs Therapeutics will post -0.65 earnings per share for the current year.

Insider Activity at Y-mAbs Therapeutics

In related news, insider Thomas Gad sold 10,810 shares of Y-mAbs Therapeutics stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $5.23, for a total value of $56,536.30. Following the completion of the transaction, the insider now owns 202,721 shares in the company, valued at $1,060,230.83. The trade was a 5.06% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 22.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Y-mAbs Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of YMAB. Brooklyn Investment Group boosted its holdings in shares of Y-mAbs Therapeutics by 4,563.8% during the 1st quarter. Brooklyn Investment Group now owns 5,923 shares of the company's stock worth $26,000 after purchasing an additional 5,796 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new position in shares of Y-mAbs Therapeutics during the 4th quarter worth approximately $46,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Y-mAbs Therapeutics during the 1st quarter worth approximately $49,000. Corton Capital Inc. acquired a new position in shares of Y-mAbs Therapeutics during the 1st quarter worth approximately $55,000. Finally, EntryPoint Capital LLC acquired a new position in shares of Y-mAbs Therapeutics during the 1st quarter worth approximately $56,000. Hedge funds and other institutional investors own 70.85% of the company's stock.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.